Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SDCBP2 antisense RNA 1 (SDCBP2-AS1) is a long non-coding RNA (lncRNA) gene that regulates various cellular processes including cell proliferation, migration, and apoptosis[1][2]. It functions primarily by interacting with proteins (such as hnRNP K and YBX1) and acting as a sponge for microRNAs, thereby influencing gene expression[1][2]. SDCBP2-AS1 has been shown to suppress tumorigenesis and metastasis in gastric cancer by destabilizing β-catenin and inhibiting oncogenic pathways[2]. Expression levels of SDCBP2-AS1 may serve as a prognostic marker in certain cancers such as gastric and ovarian cancer, and it is considered a potential target for therapeutic intervention, though no drugs currently directly target this molecule[2][1][3].
Therapeutic modulation often proposed via RNA interference, antisense oligonucleotides, or targeted RNA delivery, but none directly approved or widely used
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SDCBP2 antisense RNA 1 (SDCBP2-AS1).